Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Increased by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. raised its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 10.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,580 shares of the biopharmaceutical company’s stock after purchasing an additional 1,854 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Ultragenyx Pharmaceutical were worth $824,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of RARE. True Wealth Design LLC bought a new position in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at approximately $43,000. Values First Advisors Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical in the third quarter worth $56,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth $83,000. Nomura Asset Management Co. Ltd. acquired a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at $93,000. Finally, R Squared Ltd bought a new position in Ultragenyx Pharmaceutical in the 4th quarter worth $103,000. 97.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 11,727 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $42.23, for a total value of $495,231.21. Following the completion of the transaction, the chief executive officer now owns 2,183,985 shares in the company, valued at approximately $92,229,686.55. The trade was a 0.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 5.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on RARE. Wells Fargo & Company upped their price target on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, December 20th. JPMorgan Chase & Co. lowered their target price on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a report on Thursday, November 21st. Piper Sandler upped their price target on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Monday, January 13th. Wedbush restated a “neutral” rating and issued a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 22nd. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $92.43.

Ultragenyx Pharmaceutical Trading Down 0.9 %

Shares of RARE opened at $43.03 on Friday. The stock has a market cap of $3.97 billion, a PE ratio of -6.65 and a beta of 0.58. Ultragenyx Pharmaceutical Inc. has a 1 year low of $37.02 and a 1 year high of $60.37. The stock has a 50 day simple moving average of $44.29 and a 200-day simple moving average of $49.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The firm had revenue of $139.49 million during the quarter, compared to analyst estimates of $135.28 million. During the same period in the prior year, the company posted ($2.23) earnings per share. The business’s revenue for the quarter was up 42.3% compared to the same quarter last year. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.13 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.